Skip to main content

Health condition · Clinically reviewed

Neurofibroma, solitary or multiple - what it means and when to worry.

A soft, painless nerve-sheath lump that is usually harmless - but multiple lesions, plexiform disease and NF1 need a clearer plan.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, NHS England specialist commissioning and peer-reviewed sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including MEK inhibitor therapy and NF1 specialist service pathways.

Key facts

Neurofibroma at a glance.

The essentials, in plain English - what it is, the two main types, and how it’s assessed and treated in the UK today.

  • What it is

    A benign tumour arising from the cells of a peripheral nerve sheath - usually soft, slow-growing and painless.

  • Sporadic vs NF1

    Can occur as a single sporadic lesion, or as multiple lesions in the context of neurofibromatosis type 1 (NF1).

  • Two main types

    Cutaneous/dermal neurofibromas (small skin nodules) and plexiform neurofibromas (larger, multi-branch, NF1-associated).

  • Malignant transformation

    Plexiform lesions carry a small lifetime risk of transforming into a malignant peripheral nerve sheath tumour (MPNST).

  • Assessment

    Clinical examination, screening for NF1 features, and MRI for larger or plexiform lesions.

  • Newer therapy

    Selumetinib, a MEK inhibitor, is now an option for symptomatic inoperable plexiform neurofibromas in NF1.

Why this guide matters

Most are harmless - a few need a specialist eye.

A single neurofibroma is usually nothing to worry about. Multiple lesions, plexiform disease and any change in a lump change that picture.

  • Solitary lesions are usually sporadic

    A single, soft, painless nodule with no other features rarely needs anything beyond simple observation.

  • Multiple lesions point to NF1

    Several neurofibromas, especially with cafe-au-lait patches, warrant screening for neurofibromatosis type 1.

  • Plexiform disease needs monitoring

    Larger, multi-branch lesions carry a small lifetime risk of malignant transformation and benefit from regular specialist review.

How the diagnosis is made

From first lump to a clear plan.

The steps a UK GP, dermatologist or specialist NF1 team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Clinical examination

    A soft, painless, skin-coloured or slightly pigmented nodule is assessed for size, number and consistency.

  2. 02

    Assessing

    Screen for NF1 features

    Cafe-au-lait spots, Lisch nodules, axillary freckling and family history all point towards underlying neurofibromatosis.

  3. 03

    Assessing

    Solitary or multiple?

    A single lesion is usually sporadic. Multiple lesions raise the likelihood of NF1 - see /conditions/neurofibromatosis-type-1/.

  4. 04

    Confirming

    MRI for larger or plexiform disease

    Imaging maps the extent of a plexiform neurofibroma and its relationship to surrounding nerves and structures.

  5. 05

    Confirming

    Biopsy if concerning features

    Rapid growth, new pain or hardening suggest possible malignant transformation and warrant tissue sampling.

  6. 06

    Planning

    Genetic counselling and testing

    Offered where NF1 is suspected, to confirm the diagnosis and discuss implications for the wider family.

  7. 07

    Planning

    Specialist MDT referral

    NF1-associated disease is best managed through a commissioned dermatology, neurosurgery and genetics multidisciplinary team.

Typical timeline: a first visit to a settled monitoring plan in a matter of weeks.

Symptoms

What a neurofibroma actually looks like.

From a single soft nodule to multiple lesions and plexiform disease. And the features that mean it’s time to escalate.

  • Soft, painless nodule

    The classic dermal neurofibroma - a soft, mobile, skin-coloured or slightly pigmented lump.

  • Solitary sporadic lesion

    Most neurofibromas occur alone, in someone with no wider neurofibromatosis.

  • Multiple lesions

    Numerous cutaneous neurofibromas across the body are a hallmark of NF1.

  • Plexiform enlargement

    A larger, diffuse swelling that can involve multiple nerve branches and cause visible disfigurement.

  • Nerve-related symptoms

    Pain, weakness or numbness where a plexiform lesion presses on adjacent nerves or structures.

  • Cafe-au-lait patches

    Flat, coffee-coloured skin patches that often accompany multiple neurofibromas in NF1.

  • Skin changes over time

    Lesions can slowly enlarge or become more numerous over years, particularly through puberty.

  • Red flag - rapid growth or pain

    Sudden growth, new pain or a hardening lesion needs urgent assessment for possible MPNST.

Treatment

How neurofibroma is managed in the UK.

Observation for most, surgery for symptomatic or uncertain lesions, and newer drug therapy for inoperable plexiform disease in NF1.

  • Watchful observation

    For small, asymptomatic, stable lesions - regular review rather than active treatment.

  • Surgical excision

    Offered for symptomatic, disfiguring, or diagnostically uncertain lesions, especially where malignancy cannot be excluded.

  • MEK inhibitor (selumetinib)

    A newer option for symptomatic, inoperable plexiform neurofibromas in NF1 - can shrink tumour volume and ease symptoms.

  • Regular imaging surveillance

    Plexiform lesions are monitored periodically given their small lifetime risk of malignant transformation to MPNST.

  • Genetic counselling

    For NF1-associated disease - explaining inheritance, family screening and reproductive options.

  • Pain and symptom management

    Analgesia and, where needed, input from pain specialists for nerve compression symptoms.

  • MDT specialist care

    Commissioned dermatology, neurosurgery and genetics teams coordinate care for NF1-associated neurofibromas.

  • Urgent MPNST pathway

    Suspected malignant transformation triggers urgent biopsy and sarcoma-service referral.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist commissioning standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist team knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • NHS England. Specialised commissioning for neurofibromatosis type 1 services.

  • NICE. Selumetinib for treating symptomatic inoperable plexiform neurofibromas in neurofibromatosis type 1 (TA870).

  • Neurofibromatosis Association / Children’s Tumour Foundation. Patient guidance on neurofibromas and NF1.

  • MHRA. Selumetinib (Koselugo) licensing and monitoring information.

Red flags

When a neurofibroma needs urgent attention.

Most neurofibromas are manageable with routine review. These are the situations that aren’t - and where a specialist opinion is needed.

  • Rapid growth

    A neurofibroma that suddenly enlarges over weeks rather than years needs urgent specialist review.

  • New or worsening pain

    Pain developing in a previously painless lesion is a recognised warning sign of malignant transformation.

  • Change in texture

    A lesion that becomes hard or fixed to underlying tissue, rather than soft and mobile, needs assessment.

  • New neurological deficit

    New weakness, numbness or altered sensation suggests significant nerve involvement or compression.

  • Suspected MPNST

    Any combination of rapid growth, pain and hardening in a plexiform lesion should trigger an urgent sarcoma-pathway referral.

  • Undiagnosed NF1 features

    Cafe-au-lait spots, Lisch nodules or a strong family history in someone with neurofibromas warrants genetics referral.

  • Spinal cord compression

    Plexiform disease near the spine causing back pain, gait change or bladder/bowel symptoms is a neurosurgical emergency.

  • Visual disturbance in children with NF1

    New visual symptoms in a child with NF1 may indicate an optic pathway glioma and need prompt ophthalmology and neurology review.

  • Significant disfigurement

    Plexiform lesions causing major cosmetic or functional impact deserve early specialist surgical opinion, not delay.

Living with it

A manageable condition, with the right monitoring.

Four things that make the biggest difference over time - knowing your baseline, addressing the emotional impact, genetic clarity and staying under specialist review.

A quiet reminder

Change, not size alone, is what matters most.

A lesion that has looked the same for years is reassuring. It is new growth, pain or hardening that deserves attention.

  1. 01 Monitor

    Know your baseline

    Photograph and note the size, shape and feel of lesions so any change is easy to spot early.

  2. 02 Support

    Address the psychological impact

    Visible or multiple neurofibromas can affect confidence - support and, where needed, counselling help.

  3. 03 Family

    Consider genetic counselling

    If NF1 is confirmed, genetic counselling clarifies inheritance risk and options for family members.

  4. 04 Team

    Stay under specialist review

    NF1-associated disease benefits from ongoing multidisciplinary care rather than one-off assessment.

Frequently asked

Everything we get asked about neurofibroma.

Quick answers on sporadic lesions, NF1, plexiform disease and malignant transformation.

  • What is a neurofibroma?

    A benign tumour that arises from the cells of a peripheral nerve sheath. It usually feels soft, mobile and painless, and can occur as a single sporadic lesion or as multiple lesions in someone with neurofibromatosis type 1.

  • Is a neurofibroma the same as neurofibromatosis?

    No. A neurofibroma is the individual tumour. Neurofibromatosis type 1 (NF1) is the genetic condition that can cause multiple neurofibromas alongside other features such as cafe-au-lait spots - see /conditions/neurofibromatosis-type-1/.

  • Can I have a neurofibroma without having NF1?

    Yes. Most neurofibromas are solitary and sporadic, occurring in people with no wider neurofibromatosis. Multiple lesions, especially alongside cafe-au-lait spots or a family history, are what prompt assessment for NF1.

  • Do neurofibromas always need to be removed?

    No. Small, stable, asymptomatic lesions are often simply observed. Surgery is reserved for lesions that are symptomatic, disfiguring, or where the diagnosis is uncertain.

  • What makes a plexiform neurofibroma different?

    Plexiform neurofibromas are larger, can involve multiple nerve branches, are strongly associated with NF1, and carry a small lifetime risk of transforming into a malignant peripheral nerve sheath tumour (MPNST) - see /conditions/nerve-sheath-tumors/.

  • Can a neurofibroma turn cancerous?

    Malignant transformation is rare overall but is a recognised risk with plexiform neurofibromas in NF1. Rapid growth, new pain or a hardening lesion should always prompt urgent specialist review.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.